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Abstract
The phosphatidylinositol 3-kinase (PI3K) pathway plays an important role in many biological processes, including cell cycle
progression, cell growth, survival, actin rearrangement and migration, and intracellular vesicular transport. However, the
involvement of the PI3K pathway in the regulation of mitotic cell death remains unclear. In this study, we treated HeLa cells
with the PI3K inhibitors, 3-methyladenine (3-MA, as well as a widely used autophagy inhibitor) and wortmannin to examine
their effects on cell fates using live cell imaging. Treatment with 3-MA decreased cell viability in a time- and dose-dependent
manner and was associated with caspase-3 activation. Interestingly, 3-MA-induced cell death was not affected by RNA
interference-mediated knockdown (KD) of beclin1 (an essential protein for autophagy) in HeLa cells, or by deletion of atg5
(an essential autophagy gene) in mouse embryonic fibroblasts (MEFs). These data indicate that cell death induced by 3-MA
occurs independently of its ability to inhibit autophagy. The results from live cell imaging studies showed that the inhibition
of PI3Ks increased the occurrence of lagging chromosomes and cell cycle arrest and cell death in prometaphase.
Furthermore, PI3K inhibitors promoted nocodazole-induced mitotic cell death and reduced mitotic slippage.
Overexpression of Akt (the downstream target of PI3K) antagonized PI3K inhibitor-induced mitotic cell death and
promoted nocodazole-induced mitotic slippage. These results suggest a novel role for the PI3K pathway in regulating
mitotic progression and preventing mitotic cell death and provide justification for the use of PI3K inhibitors in combination
with anti-mitotic drugs to combat cancer.
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Introduction
Phosphatidylinositol 3-kinases (PI3Ks) phosphorylate the 3-
hydroxyl group of the inositol ring in phosphatidylinositol lipids,
which in turn coordinate the localization and function of multiple
effector proteins by binding to their specific lipid binding domains.
At the cellular level, the PI3K pathway plays an important role in
many biological processes, including cell cycle progression, cell
survival, growth, migration and intracellular vesicular transport
[1]. Aberrant activation of PI3Ks has been observed in a broad
spectrum of human tumors [2] and is thought to confer tumors
with resistance to various anti-cancer drugs and irradiation
[3,4,5,6].
Mitotic cell death is a mode of cell death occurring specifically
during mitotic stages. Inducers of mitotic cell death include DNA
damaging agents and spindle poisons/mitotic inhibitors, which
activate the spindle assembly checkpoint, causing prolonged
mitotic arrest and subsequent cell death during mitosis [7]. Cells
that become arrested in mitosis may also slip out of mitosis due to
gradual cyclinB1 degradation. This mitotic slippage may lead to
the generation of tetraploid cells, which greatly restricts the use of
anti-mitotic drugs in cancer treatment [8]. Thus, elucidation of the
pro-death signaling pathway during prolonged mitotic arrest is
important to improve the tumor-killing effects of anti-mitotic
drugs. Various kinase signaling pathways have all been suggested
to play a role in regulating cell death during mitotic arrest,
including p38 mitogen-activated protein kinases kinase (MAPK),
extracellular signal-regulated kinase (ERK), c-Jun N terminal
kinase, p21-activated kinase (PAK) [9,10,11], and apoptosis
regulators Bcl2, Bcl-xL, caspase-2/9, survivin and p73
[12,13,14,15]. Inhibition of PI3Ks has been reported to sensitize
tumors to the anti-mitotic drug -paclitaxel [5,16], implying that
the PI3K pathway might be involved in cell death regulation
during mitotic arrest. However, additional data are needed to fully
support this claim.
Autophagy is an evolutionarily conserved eukaryotic degrada-
tion pathway involved in the turnover and elimination of cellular
proteins and organelles. The autophagic process is characterized
by the formation of autophagosomes (double-membraned cytosolic
vesicles) and subsequent lysosomal degradation of constituents
contained in these vesicles [17]. Many genes involved in
autophagy, including beclin1 and atg5, were initially discovered
in yeast. Homologues have been identified in higher eukaryotes,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35665and autophagy has been shown to function in various physiological
and pathological processes [18,19].
Recently reported evidence suggests the importance of autoph-
agy in cancer development and the response to cancer treatment.
3-methyladenine (3-MA), a drug that suppresses the autophagic/
lysosomal pathway by inhibiting Class III PI3Ks [20], has been
widely used to study the role of autophagy in many research areas,
including tumorigenesis and cancer therapy. Recently, 3-MA has
been reported to cause cancer cell death under both normal and
starvation conditions, which suggests that autophagy inhibitors
may be useful for killing tumor cells [21,22]. However, 3-MA
could also suppress cell migration and invasion independently of
its ability to inhibit autophagy, implying that 3-MA possesses
functions other than autophagy suppression [22]. Thus, whether
3-MA induces cell death solely by inhibiting autophagy remains
unknown.
In this study, we examined the effects of two PI3K inhibitors (3-
MA and wortmannin) on mitotic cell death using live cell imaging.
Our results indicate that 3-MA-induced cell death occurred
independently of autophagy suppression. Live cell imaging studies
demonstrated that treatment with PI3K inhibitors led to increased
lagging chromosomes, prolonged arrest and significant cell death
in prometaphase. Moreover, treatment with PI3K inhibitors
further promoted nocodazole-induced mitotic cell death and
reduced mitotic slippage. Overexpression of PI3K downstream
target Akt antagonized PI3K inhibitor-induced mitotic cell death
and promoted nocodazole-induced mitotic slippage. These results
revealed a novel role for the PI3K pathway in preventing mitotic
cell death, and provided justification for the use of PI3K inhibitors
in combination with anti-mitotic drugs to improve cancer
treatment outcomes.
Results
3-MA induced caspase-dependent cell death that is
independent of autophagy inhibition
First, we examined the autophagy inhibitory function of 3-MA.
As shown in Fig. 1A, we examined the distribution of puncta
formed by green fluorescence protein (GFP) fused with microtu-
bule-associated light chain 3 (LC3). GFP-LC3 puncta, which are
indicative of autophagy [23], were observed in 6% of HeLa cells
cultured in normal culture medium and in 98% of cells cultured in
glucose free medium. Treatment with 5 mM 3-MA decreased the
percentage of glucose-starved HeLa cells displaying GFP-LC3
puncta to 23%. To study the role of 3-MA on autophagy under
normal conditions, we treated HeLa cells with 5 mM 3-MA for 0,
12, 24 and 48 hours. As shown in Fig. 1B, the levels of LC3-I were
increasing and the levels of LC3-II were decreasing between 12
and 48 hours in cells that treated with 3-MA (Fig. 1B). Thus,
conversion of LC3-I to LC3-II was suppressed by 3-MA. This is
consistent with the autophagy-inhibitory role of 3-MA under these
conditions [23]. These results confirmed the inhibitory effects of 3-
MA on autophagy under both normal and starvation conditions.
The effect of 3-MA on the fates of HeLa cells was then
examined by trypan blue exclusion assay. As shown in Fig. 2A,
treatment of HeLa cells with 2.5 mM or 5 mM 3-MA for one day
did not affect cell viability, whereas treatment with 10 mM 3-MA
for one day caused a 25.0% decrease in cell viability. Treatment of
cells with 2.5, 5 or 10 mM 3-MA for two days caused 11.5%,
38.0% or 79.4% decrease in viability, respectively. This suggests
that 3-MA decreased cell viability in a time- and dose-dependent
manner (Fig. 2A).
To determine whether cell death induced by 3-MA required
caspase activation, we first detected caspase-3 cleavage after 3-MA
treatment. Caspase-3 is constitutively present as a 32-kD
procaspase-3, which is cleaved into two active subunits of 17 kD
and 12 kD upon activation [24]. As shown in Fig. 2B, treatment of
cells with 2.5, 5 or 10 mM 3-MA for two days clearly promoted
the cleavage of caspase-3. Addition of the pan-caspase inhibitor z-
VAD at a concentration of 100 mM almost completely prevented
the loss of cell viability induced 5 or 10 mM 3-MA (Fig. 2C).
These results suggest that 3-MA-induced cell death is caspase
dependent.
To determine whether 3-MA-induces cell death by inhibiting
autophagy, we used small interfering RNAs (siRNAs) to knock -
down the expression of the autophagy protein beclin1 in HeLa
cells. Silencing of beclin1 efficiently decreased the expression of its
target protein (Fig. 3A). However, beclin1 KD did not affect the
viability of HeLa cells. Cells transfected with siRNA specific for
beclin1 did not show a significant decrease in viability when
compared to cells transfected with non-specific control siRNA at
24, 48 or 72 hours post transfection (Fig. 3B). Furthermore,
beclin1 KD did not enhance the lethal effect of 3-MA. As shown in
Fig. 3C, siRNA-transfected HeLa cells treated with 5 mM and
10 mM 3-MA for two days displayed 33.3% and 84.4% decreases
in viability, respectively. These results were similar to the effects
observed in cells transfected with control siRNA (35.8% and
86.0% decreases in viability, respectively).
To further determine whether 3-MA could induce cell death in
autophagy-deficient cells, we examined atg52/2 MEFs, which do
not express LC3-II, and thus completely lack the capacity for
autophagy (Fig. 3D). As shown in Fig. 3E, treatment with 5 mM
and 10 mM 3-MA for two days decreased the viability of atg52/
2 MEFs by 57.2% and 92.8%, respectively. This decrease in cell
viability was significantly different from that observed in atg5+/+
MEFs (71.5% and 91.6% decreases in viability, respectively).
Collectively, these results indicate that 3-MA induces cell death
independently of its ability to inhibit autophagy.
Figure 1. 3-methyladenine (3-MA) suppressed autophagy in
HeLa cells under both glucose-free conditions and normal
conditions. (A) HeLa cells stably expressing GFP-LC3 were cultured in
DMEM supplemented with 10% FBS (control), or in glucose-free DMEM
containing 10% FBS in the absence (glucose free) or in the presence of
5 mM 3-MA (glucose free+3-MA) for 24 hours. Cells containing at least
ten dots were considered to be positive for GFP-LC3 puncta. Numbers
represent the percentage of GFP-LC3 puncta-positive cells and arrows
indicate dead cells. At least 100 cells were counted for each treatment.
(B) HeLa cells were maintained in normal cultural conditions and were
treated with 5 mM 3-MA and collected at 0, 12, 24 and 48 hours post
treatment initiation, and subjected to immunobloting.
doi:10.1371/journal.pone.0035665.g001
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cell death
PI3Ks are the only reported targets for 3-MA [22]. To
determine whether 3-MA-induced cell death was dependent on
PI3K inhibition and to examine the modes of cell death induced
by 3-MA, we treated HeLa cells with another PI3K inhibitor,
wortmannin, and subsequently performed long-term live cell
imaging to examine their behaviors. During normal mitosis
(Fig. 4A, top panel; Movie S1), chromatin became condensed
and congressed onto the metaphase plate during prometaphase.
This was followed by chromosomal segregation and decondensa-
tion to form two daughter nuclei during anaphase and telophase.
The entire mitotic process, from prophase to telophase, lasted
approximately 2.5 hours in HeLa cells. Treatment of cells with
PI3K inhibitors induced cell death during both interphase and
mitosis. For cells that died in interphase (Fig. 4A, middle panel;
Movie S2), their mother cells usually underwent mitosis and
produced two daughter cells with one daughter died before
entering the next round of mitosis. For cells that died in mitosis
(Fig. 4A, bottom panel; Movie S3), the mother cell rounded up
with the chromatin beginning to condense and congress to form a
metaphase plate, indicating that the cell was in prometaphase. It
stayed in prometaphase for about six hours before the signs of
apoptotic cell death appeared, including wrinkling of the plasma
membrane, collapse of the cytoplasm and the condensation or
fragmentation of the nuclei. As shown in Fig. 4B and C, 9.1% and
16.4% of cells died in interphase and mitosis, respectively,
following 5 mM 3-MA treatment, and 9.6% and 11.3% of cells
died in interphase and mitosis, respectively, after 50 mM
wortmannin treatment. The frequency of cell death during mitosis
or interphase was significantly higher than that observed in the
control cells (interphase: 2.0%, p,0.001; mitosis: 2.0%, p,0.001;
262 x
2 test). These results indicate that inhibitors of PI3K induced
cell death in both interphase and mitosis.
Inhibitors of PI3K promoted prometaphase chromosome
lagging and prolonged the duration of prometaphase
Mitotic cell death has been reported to occur after prolonged
mitotic arrest [7]. Using live cell imaging to record the mitotic
behaviors of single cells, we assessed the ability of PI3K inhibitors
to cause mitotic arrest. We noticed that cells often stayed in
prometaphase for several hours without entering anaphase before
dying in mitosis (Fig. 5A, top panel; Movie S4). The average
duration of prometaphse was significantly prolonged in cells
treated with 5 mM 3-MA or 50 mM wortmannin (96.6 min for 3-
MA; 96.2 min for wortmannin; Fig. 5C), when compared to
control cells (53.8 min, p,0.001, student’s-t test; Fig. 5C). The
duration of prometaphase was even longer for cells that died in
mitosis (361.8 min for 3-MA; 295.7 min for wortmannin; Fig. 5C).
Thus, PI3K inhibitor-treated cells showed a prolonged prometa-
phase before undergoing cell death.
Lagging chromosomes that do not align onto the metaphase
plate could activate the spindle assembly checkpoint and cause
prolonged prometaphase [25]. We thus closely examined the
behaviors of chromosomes during mitosis, and found that
chromosomal laggards often lingered outside the metaphase plate,
Figure 2. 3-MA induced caspase-dependent cell death in HeLa cells. (A) HeLa cells were treated with 0, 2.5, 5 and 10 mM 3-MA. Cells were
collected 0, 1 and 2 days post treatment initiation and subjected to trypan blue exclusion assay. At least 300 cells were counted for each sample. Bars
represent standard deviation from three independent experiments. (B) Caspase-3 was activated upon 3-MA treatment. HeLa cells were treated with 0,
2.5, 5 or 10 mM 3-MA, and cells were collected and subjected to immunobloting 2 days post treatment initiation. Activation of caspase-3 was
assessed with antibodies specific for both procaspase-3 and its active cleaved subunits. The molecular weight of cleaved subunits of caspas-3 is
indicated. This blot is representative of three independent experiments. (C) z-VAD effectively antagonized 3-MA-induced cell death. HeLa cells were
treated with 0, 5 or 10 mM 3-MA in the presence of 100 mM z-VAD or DMSO (used as a solvent control). Two days after treatment, the cells were
collected and subjected to a trypan blue exclusion assay. At least 300 cells were counted for each sample. Bars represent the standard deviations
from three independent experiments.
doi:10.1371/journal.pone.0035665.g002
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Movie S5). 13.9% of 3-MA treated cells and 13.1% of
wortmannin-treated cells displayed lagging chromosomes at
prometaphase, as compared to 1.3% of control cells (Fig. 5B).
PI3K inhibitors promoted nocodazole induced mitotic
cell death and reduced mitotic slippage
The duration of prometaphase before Hela cells died in mitosis
was approximately five to six hours after treatment with PI3K
inhibitors (Fig. 5C). This timeframe was much shorter than that of
cells treated with classic anti-mitotic drugs such as nocodazole
[26,27,28]. This implies that PI3K inhibition may potentially
accelerate the process of mitotic cell death. To confirm this
finding, we treated HeLa cells with nocodazole, a classic anti-
mitotic drug, in combination with 3-MA or wortmannin and
examined cell death using live cell imaging. After treatment with
100 nM nocodazole, approximately 40% of cells exhibited mitotic
slippage, while the remainder exhibited mitotic cell death (Fig. 6D
and F). For those exhibited mitotic cell death, the cell entered
mitosis and stayed in mitosis for approximately eight hours without
forming a metaphase plate and then committing to death (Fig. 6A,
top panel; Movie S6). For those cells that exhibited mitotic
slippage, the cell entered mitosis and stayed in mitosis for greater
than ten hours, then decondensed its chromosomes without
undergoing anaphase, finally forming one daughter cell in
interphase (Fig. 6B, bottom panel; Movie S7).
We next treated cells with 1 mM 3-MA or 10 mM wortmannin
alone, or in combination with 100 nM nocodazole and examined
cell death using live cell imaging. Treatment of HeLa cells with
1 mM 3-MA or 10 mM wortmannin alone did not cause
significant cell death (Fig. 2A and 6B). However, 3-MA
significantly shortened the duration of nocodazole-induced-
prometaphase arrest (from 546.2 min to 426.4 min, p,0.001;
student’s t test, Fig. 6C) and reduced the occurrence of
Figure 3. 3-MA-induced cell death occurred independently of the inhibition of autophagy. (A) Immunoblot showing the efficiency of
beclin1 silencing in HeLa cells. Cells were transiently transfected with negative control (NC) siRNAs or siRNAs specific for beclin1 mRNAs. The cells
were collected and subjected to immunobloting 48 hours post-transfection. The blot shown is representative of three independent experiments. (B)
Beclin1 KD did not cause cell death in HeLa cells. Cells were transiently transfected with negative control (NC) siRNAs or siRNAs specific for beclin1
mRNAs. Cell viability was determined using a trypan blue exclusion assay at 24, 48 and 72 hours post transfection. (C) Beclin1 KD had no effects on 3-
MA-induced cell death. Twenty four hours post transfection with NC siRNAs or siRNAs against beclin1, HeLa cells were treated with 0, 5 or 10 mM 3-
MA. Cell viability was determined 48 hours post treatment using trypan blue exclusion assay. (D) Immunoblot showing atg5 and LC3 levels in atg5+/+
and atg52/2 MEFs. (E) Atg5+/+ and atg52/2 MEFs were treated with 0, 5 or 10 mM 3-MA. Then cell viability were determined 48 h post treatment
using trypan blue exclusion assay. At least 300 cells were counted for each treatment to determine cell viability and bars represent the standard
deviations from three independent experiments.
doi:10.1371/journal.pone.0035665.g003
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p,0.001; 262 x
2 test, Fig. 6D). Similar results were obtained
with wortmannin treatment (Fig. 6E and F). These results indicate
that PI3K inhibition promoted nocodazole-induced mitotic cell
death and reduced mitotic slippage.
Akt overexpression antagonized PI3K inhibitor-induced
mitotic cell death and promoted nocodazole-induced
mitotic slippage
3-MA or wortmannin may possess off-target effects other than
inhibition of PI3Ks; thus, we transiently expressed a constitutively
active form of Akt in HeLa cells to test whether Akt overexpression
could reverse the effects of PI3K inhibitors on cell death.
Transfection of HeLa cells with a control vector harboring GFP
had little effect on 3-MA- or wortmannin-induced cell death
(Fig. 7B, C, D and E). However, expression of GFP-Akt
significantly reduced both interphase cell death and mitotic cell
death induced by treatment with 5 mM 3-MA (interphase: from
10.0% to 4.3%, p,0.01; mitosis: from 17.6% to 5.7%, p,0.01;
262 x
2 test; Fig. 7B and C). Similar results were obtained with
50 mM wortmannin (interphase: from 10.2% to 3.8%, p,0.01;
mitosis: from 13.3% to 4.3%, p,0.05, 262 x
2 test, Fig. 7D and E).
The effects of Akt overexpression on cell death in nocodazole
treated cells were also investigated. As expected, expression of
GFP itself had little effect on nocodazole-induced mitotic slippage
(Fig. 7F). However, expression of GFP-Akt construct significantly
increased the occurrence of nocodaozle-induced mitotic slippage
(from 41.4% to 69.1%, p,0.001, 262 x
2 test; Fig. 7F). Taken
together, these results indicate that Akt overexpression antago-
nized PI3K inhibitor-induced mitotic cell death and promote
nocodazole-induced mitotic slippage.
Discussion
3-MA is a widely used inhibitor of autophagy, and it has been
reported to cause HeLa cell death under both normal and
starvation conditions, leading to the hypothesis that autophagy
inhibitors may be useful for killing tumor cells [21,22]. In this
study, we consistently found that 3-MA increased HeLa cell death
in a time- and dose-dependent manner (Fig. 2A). However,
beclin1 down-regulation did not induce HeLa cell death, nor did it
affect 3-MA-induced cell death (Fig. 3B and C). Moreover, 3-MA
treatment induced significant cell death in autophagy-deficient
atg52/2 MEFs (Fig. 3E). These results indicated an autophagy-
independent inhibitory function of 3-MA in inducing cell death.
Thus, special cautions should be taken when interpreting the
results obtained with similar types of autophagy inhibitors.
Notably, a significant difference in cell viability was observed
between atg5+/+ and atg52/2MEFs when treated with 5 mM 3-
MA (Fig. 3E). This might be due to the apoptosis-promoting
function of atg5 [29].
Figure 4. PI3K inhibitors induced cell death in both interphase and mitosis. HeLa cells were stably transfected with mCherry tagged
histone-2B to visualize the nuclei. The cells were treated with 5 mM 3-MA or 50 mM wortmannin, and live cell imaging was performed for 48 hours.
(A) Representative live cell imaging records of normal mitotic process (top panel), interphase cell death (middle panel) and mitotic cell death (bottom
panel). Time is shown as hours: minutes. (B) Quantification of 3-MA or wortmannin induced interphase cell death. (C) Quantification of 3-MA- or
wortmannin-induced mitotic cell death. n: the number of cells analyzed. *: p,0.001, 262 x
2 test, compared to the control. Error bars represent the
standard deviations from two independent experiments.
doi:10.1371/journal.pone.0035665.g004
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used another PI3K inhibitor (wortmannin) to treat HeLa cells and
tracked cell death using live cell imaging. Consistent with previous
reports [4,30], inhibition of PI3Ks was observed to cause cell death
in interphase. We found that inhibition of PI3Ks induced cell
death during mitosis and that overexpression of the PI3K
downstream target Akt antagonized PI3K inhibitor-induced
mitotic cell death. Live cell imaging studies further showed that
PI3K inhibitors induced prometaphase chromosome lagging and
prolonged the duration of prometaphase. These results revealed a
novel role for the PI3K pathway in regulating cell cycle
progression during mitosis and preventing mitotic arrest.
Mitotic cell death is defined as a mode of cell death that occurs
during mitosis. Various anti-mitotic drugs have been shown to
induce cell death during mitosis. These drugs include taxanes,
Vinca alkaloids and kinesin inhibitors, which interfere with the
functions of mitotic spindle apparatus, DNA damaging agents,
which activate the spindle assembly checkpoint, or other
treatments that prevent mitotic exit through mechanisms such as
CDC20 down-regulation [26,31]. In this study, we found that
PI3K inhibitor-treated cells frequently displayed lagging chromo-
somes at prometaphase (Fig. 5A and B). This implies that the
microtubule-kinetochore attachment may be impaired in cells
treated with PI3K inhibitors, thus activating the spindle assembly
checkpoint and causing mitotic arrest and cell death during
mitosis. Disruption of microtubule-kinetochore attachments has
been shown to cause mitotic cell death. Depletion of hNuf2, a
kinetochore protein essential for microtubule attachment, induced
mitotic arrest and subsequently mitotic cell death [32]. Further-
more, expression of a dominant negative Plk1, which are involved
in microtubule-kinetochore attachment, caused mitotic cell death
in HeLa cells [33,34]. Whether PI3K inhibition-induced mitotic
cell death involves one of these proteins or other unknown factors
remains to be determined.
Mitotic cell death may occur in a caspase-dependent or -
independent manner. Inhibition of Chk2 in syncytia generated by
fusion of asynchronous HeLa cells caused mitotic cell death
accompanied by sequential caspase-2 activation, cytochrome C
release from mitochondira, caspase-3 activation and DNA
fragmentation [35]. Anti-mitotic drugs, including nocodazole,
taxol or kinesin-5 inhibitor, have also been shown to cause mitotic
cell death mediated by caspase activation [27,36]. However, in
bub1 deficient cells, conditions that activate the spindle check-
points (i.e., cold shock or treatment with nocodazole, paclitaxel, or
17-AAG) induced caspase-independent mitotic death and required
apoptosis-inducing factor and endonuclease G [37]. In this study,
treatment with PI3K inhibitors activated caspase-3, and the pan-
caspase inhibitor z-VAD almost completely antagonized PI3K
inhibitor-induced cell death (Fig. 2B and C). The results of live cell
imaging studies showed that PI3K inhibitor-treated cells displayed
signs of apoptosis, including wrinkled plasma membrane, collapsed
cytoplasm and condensed or fragmented nuclei. These results
indicate that 3-MA-induced mitotic cell death occurred through
caspase-dependent apoptosis.
The underlying trigger for mitotic cell death during prolonged
mitotic arrest is currently unclear. Spindle assembly checkpoint
(SAC) has long been thought to play critical roles during this
process. A recent study showed that silencing of SAC proteins did
not affect the mitotic arrest or mitotic cell death induced by down-
regulation of CDC20 or expression of degradation-resistant cyclin
B1 [26]. This leads to the suggestion that some general features of
mitotic arrest, rather than SAC itself, are the proximal trigger for
death during mitosis. Nevertheless, the molecular nature of the
signal that triggers cell death during prolonged mitotic arrest
remains poorly defined. PI3K inhibitors have also been reported
to sensitize tumor cells to antimitotic drugs including paclitaxel
[5,16], indicating that the PI3K pathway may be involved in cell
death regulation during mitotic arrest. However, concrete
evidence supporting this conclusion is lacking. In this study we
demonstrated by live cell imaging that inhibitors of PI3K
prolonged the duration of prometaphase which was followed by
death during mitosis. Notably, PI3K inhibitor-treated HeLa cells
stayed in mitosis for only five to six hours on average before they
committed to cell death (Fig. 5A and C), and this cell death
occurred much sooner than the mitotic cell death induced by
conventional anti-mitotic drugs. It has been reported that most
HeLa cells stay in mitosis for more than ten hours before death
induced by treatment with nocodazole or kinesin5 inhibitors
[26,27,28]. This suggests that inhibition of PI3K may promote cell
death during mitotic arrest. Treatment of HeLa cells with PI3K
inhibitors in combination with nocodazole promoted mitotic cell
death and reduced mitotic slippage, and Akt overexpression
increased the occurrence of nocodazole-induced mitotic slippage
(Fig. 7). These results directly demonstrated that the PI3K-Akt
pathway plays an important role in preventing mitotic cell death.
It is interesting to note that we found PI3K inhibitors increased
the duration of prometaphase when used alone (Fig. 4C), whereas
these inhibitors decreased the time of prometaphase required to
initiate nocodazole-induced cell death (Fig. 6C and E). These
results suggest that the PI3K pathway plays multiple roles in
regulating mitotic cell death. When used alone, PI3K inhibitors
induced lagging chromosomes and caused cell cycle arrest at
prometaphase (Fig. 5). Certain pro-death signals may accumulate
during this arrest, thus leading to mitotic cell death. When used in
combination with nocodazole, PI3K inhibitors shortened the time
required to initiate nocodazole-induced cell death and reduced the
Figure 5. Inhibitors of PI3K increased chromosome lagging and
prolonged the duration of prometaphase. HeLa cells were treated
with 5 mM 3-MA or 50 mM wortmannin, and live cell imaging was
performed for 48 hours. (A) Representative live cell imaging records
showing a cell that stayed at prometaphase for more than eight hours
(top panel), with the presence of lagging chromosomes outside the
metaphase plate (bottom panel). (B) Quantification of 3-MA- or
wortmannin-induced lagging chromosomes at prometaphase. n: the
number of total cells. *: p,0.001, 262 x
2 test, compared to the control.
(C) Quantification of the duration of prometaphase under 3-MA or
wortmannin treatment. n: the number of total cells. N: the number of
cells that died in mitosis. *: p,0.001, student’s t-test, compared to the
control. Error bars represent standard deviations from the results of two
independent experiments. Time is shown as hours: minutes.
doi:10.1371/journal.pone.0035665.g005
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as a pro-survival pathway during mitotic arrest, which may confer
tumor cells with resistance to anti-mitotic drugs.
Classic anti-mitotic drugs induce cancer cell death mainly
through the activation of SAC and by increasing mitotic arrest and
mitotic cell death. However, cancer cells often slip out of mitotic
arrest before cell death due to defective SAC or gradual proteolysis
of cyclinB1, which reduces the efficacy of conventional anti-mitotic
drugs [8]. Elucidation of the pro-death signaling pathway during
prolonged mitotic arrest is important to improve the tumor killing
effects of anti-mitotic drugs. In this study, we demonstrated that
inhibition of PI3Ks promoted nocodazole-induced mitotic cell
death and reduced mitotic slippage. This finding suggests that
Figure 6. PI3K inhibitors promote nocodazole-induced mitotic cell death and reduce mitotic slippage. HeLa cells were treated with
100 nM nocodazole alone or in combination with 1 mM 3-MA or 10 mM wortmannin, and live cell imaging was performed for 48 hours. (A)
Representative live cell imaging records showing nocodazole-induced mitotic cell death (top panel) and mitotic slippage (bottom panel). (B)
Quantification of 1 mM 3-MA or 10 mM wortmannin induced cell death. #:p .0.05, 262 x
2 test, compared with the control. (C&E) The duration of
prometaphase for cells treated with 100 nM nocodazole alone or in combination with 1 m M 3-MA or 10 mM wortmannin. *: p,0.001, student’s t-
test, compared with the control. (D&F) The frequencies of mitotic cell death for cells treated with 100 nM nocodazole alone or in combination with
1 mM 3-MA or 10 mM wortmannin. *: p,0.001, 262 x
2 test, compared to the control. n: The number of cells analyzed. Error bars represent the
standard deviations from two independent experiments. Time is shown as hours: minutes.
doi:10.1371/journal.pone.0035665.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35665Figure 7. Akt overexpression antagonized PI3K inhibitor-induced mitotic cell death and promoted nocodazole induced mitotic
slippage. HeLa cells were transfected with plasmids expressing GFP or GFP-Akt and were treated with 5 mM 3-MA, 50 mM wortmannin or 100 nM
nocodazole and subjected to live cell imaging 24 hours post transfection. (A) Representative live cell imaging records showing the daughter cells of a
cell that was not transfected with GFP that underwent interphase cell death (top panel), a GFP expressing cell that underwent mitotic cell death
(middle panel) and a GFP-AKT expressing cell that underwent normal mitosis (bottom panel) in the presence of PI3K inhibitors. (B&D) Frequencies of
interphase cell death in cells treated with 5 mM 3-MA or 50 mM wortmannin. (C&E) Frequencies of mitotic cell death in cells treated with 5 mM 3-MA
or 50 mM wortmannin. (F) Frequencies of mitotic slippage in cells treated with 100 nM nocodazole. Null: cells that were not transfected with any
vectors; GFP: cells transfected with GFP expressing vectors; GFP-AKT: cells transfected with GFP-AKT expressing vectors. *: p,0.05, **: p,0.01,
***: p,0.001, 262 x
2 test, compared to the control. Error bars represent the standard deviations from two independent experiments. Time is shown
as hours: minutes.
doi:10.1371/journal.pone.0035665.g007
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35665using PI3k inhibitors in combination with anti-mitotic drugs may
improve cancer treatment outcomes.
In summary, the current study demonstrated that the inhibition
of PI3K pathway induced mitotic arrest and mitotic cell death and
promoted nocodazole-induced mitotic cell death while reducing
the occurrence of mitotic slippage. These results suggest a novel
role for the PI3K pathway in regulating cell cycle progression
during mitosis and preventing mitotic cell death, and provide
justification for the use of PI3K inhibitors in combination with
anti-mitotic drugs to combat cancer.
Materials and Methods
Cell lines and treatment
HeLa cells and MEF atg52/2, atg5+/+ cells (a generous gift
from Dr. Noboru Mizushima, Tokyo Metropolitan Institute of
Medical Science) were cultured in DMEM supplemented with
10% fetal bovine serum and 1% non-essential amino acids
(Invitrogen). H2B-mCherry-positive or GFP-LC3-positive HeLa
cells were obtained as follows. Cells were grown in a 24-well plate
(3610
4 cells per well) for 24 hours and transfected with pBOS-
H2BmCherry (mCherry expressing vector was a generous gift
from Dr. Chenbei Chang, University of Alabama at Birmingham)
or pEGFP-LC3 (kindly provided by Dr. Longping Wen,
University of Science a nd Technology of China) using
Lipofectamine 2000 transfection reagent (Invitrogen 11668-027).
Thirty hours after transfection, the cells were inoculated into 60-
mm tissue culture dishes and selected with 2 mg/ml blasticidin S
(MP Biomedicals, 150477) or 500 mg/ml G418 (GIBCO, 11811-
031) for 2 or 3 weeks. All incubations were performed at 37uCi na
humidified atmosphere of 5% CO2 and 95% air.
3-MA, which was found to inhibit autophagy at concentrations
ranging from 1 to 10 mM [20], was purchased from Sigma Aldrich
(Cat.No. 08592),and was directlydissolved intothe culture medium
at the indicated concentrations. Wortmannin (Beyotime, S1952),
nocodazole (Calbiochem, 487928) and z-VAD (Calbiochem,
627610) were dissolved in DMSO and diluted in culture medium.
Cell viability assay
Cell viability was determined by a trypan blue exclusion assay.
Briefly, both adherent and floating cells were collected and
suspended in phosphate buffered saline (PBS, pH 7.4) at a final
density of 1–2610
6/ml. An equal volume of 0.4% trypan blue
solution (w/v, in PBS) was added to the cell suspension and mixed
thoroughly. After incubation at room temperature for 3 min, cell
counting was performed using a hemacytometer.
Live cell imaging
Cells were seeded in an 8-well coverglass-bottomed chamber
(Lab-Tek II, Cat No. 155409) for 24 hours (6610
3 cells per well).
Images were acquired automatically at multiple locations on the
coverglass using a Nikon TE2000E inverted microscope fitted with
a2 0 6Nikon Plan Apo objective, a linearly-encoded stage (Proscan,
Prior) and a Hamamatsu Orca-ER CCD camera. A mercury-arc
lampwith two neutraldensityfilters(fora total128-foldreductionin
intensity) was used for fluorescence illumination. The microscope
was controlled using NIS-Elements Advanced Research software
(Nikon) and housed in a custom-designed 37uC chamber with a
secondary internal chamber that delivered humidified 5% CO2.
Fluorescence and differential interference contrast images were
obtained every 10 min for a period of 48 hours.
To analyze live cell imaging movies, the time-lapse records of live
cell imaging experiments were exported as an image series, and
analyzed manually using NIS-Elements Advanced Research
software (Nikon).Thecriteria for analysesweredescribed previously
[38], and lagging chromosomes in prometaphase were defined as
the red fluorescence-positive materials that lingered outside the
roughly formed metaphase plate for more than 3 frames (30 min).
RNA interference
siRNAs targeting beclin1 mRNA (59- CAGUUUGGCACAAU-
CAAUAUU -39) and nonspecific control siRNAs (GenePharma,
Shanghai) were used in the following experiments. Transfection
was performed using Lipofectamine 2000 (Invitrogen 11668-027).
One day prior to transfection, the cells were plated at an
appropriate density to grow to 70%–80% confluency overnight.
siRNA-Lipofectamine 2000 complexes were then prepared, and
transfection was performed according to the manufacturer’s
instructions. The cells were incubated with siRNA-liposome
complexes for 6 hours and then provided with fresh DMEM
containing 10% FBS.
Transient transfection of HeLa cells with GFP and GFP-
Akt expression vectors
HeLa cells that had reached 70%–80% confluency were
transfected with pLEGFP-N1 and pLEGFP-AKT (a generous gift
from Dr. Yizheng Wang, Chinese Academy of Science) using
Lipofectamine 2000 (Invitrogen 11668-027) according to the
manufacturer’s instructions. Twenty-four hours post-transfection,
the cells were seeded into an 8-well coverglass-bottomed chamber
(Lab-Tek II, Cat No. 155409) for additional treatment.
Western blotting
Antibodies specific for Beclin1 (Santa Cruz, SC11427), Atg5 (a
generous gift from Dr. Hans-Uwe Simon, University of Bern),
LC3 (Novus Biologicals, NB100-2220), Caspase3 (Beyotime,
AC031) and b-actin (Abcam, ab8226) were used. Western blot
analysis was performed as described previously (25). Proteins were
extracted from HeLa cells with lysis buffer (50 mM Tris (pH 7.4),
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS
and 1 mM PMSF). Equal amounts of protein (20 mg) were
separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (12% separating gel). After electrophoresis,
the proteins were transferred to nitrocellulose membranes
(200 mA for 3 hours). The blots were then blocked in 5% nonfat
dry milk solution for 1 hour at room temperature.The membrane
were incubated with the respective primary antibodies at room
temperature and then with anti-rabbit or anti-mouse alkaline
phosphatase-conjugated secondary IgG antibodies. Immune
complexes were detected with an enhanced chemiluminescence
detection method by immersing the blots in chemiluminescence
reagents (Pierce 34150) for 5–10 min and then exposing the
blotsto Kodak X-OMAT film for a few seconds.
Statistical analysis
The Student’s-t test was used to compare continuous variables
and the chi-squared (262x2) test was used to compare categorical
variables. The p-values were as shown and less than 0.05 was
considered statistically significant.
Supporting Information
Movie S1 Normal cell division. The cell rounded up and the
chromatins became condensed and congressed onto the meta-
phase plate during prometaphase. The chromosomes were then
segregated and decondensed to form two daughter nuclei during
anaphase and telophase, generating two daughter cells.
(AVI)
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35665Movie S2 Interphase cell death. The cell underwent mitosis
and produced two daughter cells. One daughter cell died before
entering the next round of mitosis.
(AVI)
Movie S3 Mitotic cell death. The cell rounded up as the
chromatin began to condense and congress to form a metaphase
plate, then the cell died without entering anaphase.
(AVI)
Movie S4 Prolonged duration in prometaphase. This cell
entered mitosis and stayed in mitosis for many frames (10 min/
frame).
(AVI)
Movie S5 Lagging chromosomes. This cell entered mitosis
but stayed in prometaphase, with the red fluorescent-positive
materials observed outside the roughly formed metaphase plate.
(AVI)
Movie S6 Nocodazole induced mitotic cell death. The cell
entered mitosis and stayed in mitosis for a prolonged period
without forming a metaphase plate before committing to death.
(AVI)
Movie S7 Nocodazole-induced mitotic slippage. The cell
entered mitosis and stayed in mitosis for a prolonged period, and
then decondensed its chromosomes without undergoing anaphase.
One daughter cell was finally formed in interphase.
(AVI)
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